“South Africa’s regulated Single Exit Price (SEP) for medicines and scheduled substances increased by 2.88% from 1 October 2026, marking the second medicine-price adjustment of the year and affecting medicines sold through the private healthcare sector. The Department of Health says the extraordinary adjustment is intended to help pharmaceutical manufacturers deal with rising input costs, supply-chain pressures and geopolitical disruptions while supporting continued medicine availability.”
South Africa introduces second medicine price adjustment of 2026
South African patients using private pharmacies and other private-sector medicine suppliers are facing a new change in the cost of medicines following the implementation of an extraordinary 2.88% increase in the Single Exit Price (SEP). The adjustment became effective on 1 October 2026, meaning it is now in force across the private pharmaceutical market.
The Department of Health announced the measure on 30 September, describing it as the second extraordinary adjustment to medicine prices in 2026. The increase applies to registered medicines and scheduled substances that were listed on South Africa’s national medicines database as at 30 September, including their different pack sizes.
The development is significant because medicine prices directly affect patients who rely on chronic prescriptions, specialist treatment and other medicines obtained through the private healthcare system. At the same time, the government says the adjustment is intended to address pressures that could threaten the ability of manufacturers and suppliers to keep medicines available.
The latest measure therefore places affordability and medicine supply at the centre of an ongoing debate about how South Africa should manage pharmaceutical prices.
Why medicine prices have been adjusted
According to the Department of Health, the decision followed sustained discussions between government and representatives of the pharmaceutical industry. Those discussions identified rising production costs, supply-chain pressures and geopolitical factors as risks to medicine availability.
The pharmaceutical industry has argued that manufacturers have been dealing with substantially higher costs for production inputs and logistics. Business Day reported that industry representatives had warned of medicine shortages and increasing pressure on manufacturers to absorb costs. The report said pharmaceutical representatives linked some of the pressures to geopolitical developments, disruptions affecting energy and transportation costs, and changes in the value of the rand.
The government therefore faced a balancing exercise. On one side is the need to protect patients from excessive increases in healthcare costs. On the other is the need to ensure that manufacturers can continue producing and importing medicines in a market where costs have increased.
The Department of Health says the 2.88% adjustment is designed to provide temporary relief to manufacturers while attempting to maintain affordability for patients and medical schemes.
What the Single Exit Price means
The Single Exit Price, commonly known as SEP, is the regulated maximum price at which manufacturers and importers can sell medicines in South Africa’s private sector.
The system applies to sales to buyers including pharmacies, dispensing doctors and private hospitals. The Department of Health explains that the SEP framework is intended to improve predictability in medicine pricing and prevent manufacturers or importers from charging different buyers different prices for the same medicine.
Importantly, the latest adjustment does not apply to medicines supplied through the state in the same way, because the SEP is specifically a private-sector pricing mechanism.
That distinction matters for South Africans because the country has both a large public healthcare system and a private healthcare sector. Patients receiving medicines through public facilities are therefore not affected by the SEP increase in the same manner as patients purchasing medicines through private pharmacies.
For private-sector patients, however, the adjustment can affect the regulated price of medicines from October.
Why the increase is described as extraordinary
The latest adjustment is unusual because it is the second SEP adjustment during 2026.
The Department of Health normally reviews medicine prices through the established annual pricing process. Earlier in 2026, the industry received a 1.47% adjustment, according to Business Day and comments reported by EWN. Pharmaceutical industry representatives argued that the earlier increase did not fully compensate manufacturers for rising costs.
The government subsequently engaged with pharmaceutical companies and other stakeholders about the pressures affecting medicine supply.
EWN reported that Pharmisa chairperson Stavros Nicolaou said the industry had experienced substantial increases in manufacturing input costs following developments during the year. He argued that the additional adjustment was necessary to help sustain supply, while acknowledging the pressure that higher prices place on households.
The Department of Health ultimately announced the additional 2.88% adjustment, describing it as an extraordinary measure.
Potential effect on patients
For patients, the most immediate concern is what the adjustment means at the pharmacy counter.
A 2.88% increase does not mean that every medicine prescription will automatically become 2.88% more expensive in the same way. The actual rand effect depends on the medicine’s existing price and other factors affecting the final cost paid by a patient.
Nevertheless, patients who regularly purchase medicines privately may notice higher costs.
This is particularly relevant to people who require long-term treatment. A patient purchasing a medicine once may experience a relatively small change, while someone purchasing several prescriptions every month could see the additional costs accumulate over time.
Medical schemes may also have to account for medicine-cost pressures when managing healthcare expenditure.
The Department of Health says the adjustment is intended to maintain a balance between affordability and sustainable supply.
That balance is important because keeping prices artificially low without accounting for production and supply costs can create challenges for manufacturers. However, increasing medicine prices can also place additional pressure on patients and healthcare budgets.
Medicine availability remains a major concern
The issue is not simply about price.
Medicine availability has become an important part of the discussion surrounding South Africa’s pharmaceutical sector. Business Day reported that industry representatives had warned of shortages emerging as manufacturers faced increasing costs.
The Department of Health has previously said that medicine availability can be affected by international manufacturing disruptions, shortages of raw materials, transportation delays, increased global demand and procurement changes.
In September, the department assured the public that the public healthcare system’s medicine supply remained stable. It also explained that patients may sometimes receive medicines with different packaging, colours or manufacturers because multiple approved suppliers can provide equivalent products.
The department said such products can contain the same active ingredients and strength and may be clinically interchangeable when appropriately approved.
This highlights the difference between a medicine shortage and the temporary unavailability of a particular brand, pack size or supplier’s product.
Government and industry face a difficult balance
The latest adjustment illustrates a broader challenge facing South Africa’s healthcare system: how to keep medicines accessible while ensuring that the pharmaceutical industry remains capable of supplying them.
Manufacturers face expenses associated with raw materials, energy, transportation, labour, packaging, regulation and international supply chains. When these costs rise significantly, companies may face pressure if regulated medicine prices do not move accordingly.
At the same time, patients cannot necessarily absorb every increase.
The Department of Health has therefore framed the 2.88% adjustment as a temporary response to exceptional conditions rather than simply a routine price increase. The department says it expects the measure to provide manufacturers with relief while supporting continued medicine availability.
Industry representatives, meanwhile, have indicated that the additional adjustment only provides partial relief and that discussions about longer-term pharmaceutical sustainability will continue.
What happens next?
The medicine-pricing debate is unlikely to end with the October adjustment.
The next regular pricing cycle will become important as government, manufacturers, medical schemes and other stakeholders assess whether current medicine prices adequately reflect production and distribution costs.
The pharmaceutical industry is also expected to continue discussions with government about supply stability and pricing.
For patients, the key issue will be whether the additional adjustment contributes to more reliable medicine availability without creating excessive pressure on healthcare budgets.
The Department of Health has previously said it monitors medicine availability through national surveillance mechanisms and works with provinces, healthcare facilities, suppliers and regulators to identify potential supply problems.
Conclusion
South Africa’s 2.88% Single Exit Price adjustment, effective from 1 October 2026, represents a significant development in the country’s medicine sector because it comes after an earlier price adjustment during the year.
The government says the measure responds to exceptional domestic and geopolitical pressures, including rising input and supply-chain costs, and is intended to help protect medicine availability. Pharmaceutical industry representatives have argued that manufacturers have faced substantial cost increases and warned about pressures affecting supply.
For patients using the private healthcare sector, the change means that the regulated price of affected medicines is now higher. However, the measure does not apply to state-provided medicines through the SEP mechanism.
The development ultimately reflects the difficult relationship between medicine affordability, pharmaceutical sustainability and reliable access to treatment. As South Africa moves toward the next medicine-pricing cycle, government and industry will continue to face pressure to ensure that medicines remain available while keeping healthcare costs manageable for patients.
